Evolent Health Stock Earnings Reports

Key points for investors:

- Q1 2026 results: total revenue $496M (up 9% sequentially vs. Q4 2025, excl. divestiture), adjusted EBITDA $22M, medical expense ratio (MER) 93% (improved ~150 bps vs. Q4 2025, excl. ECP). Results were in line with company expectations.

- 2026 guidance reiterated: revenue $2.4B–$2.6B, adjusted EBITDA $110M–$140M, full-year MER ~93%.

- Business developments: successful January 1 Performance Suite launch with Aetna (early clinical intervention and provider engagement metrics above internal targets) and Highmark launch on May 1 (early stages). Pipeline remains strong, particularly in oncology.

- New contracts announced: (1) advanced imaging for an existing Performance Suite client covering ~4.5M lives (targeting Q3 go-live, pending state approvals); (2) expansion of an existing client’s oncology and cardiology Performance Suite in new markets expected to generate >$200M annual revenue (Q3 go-live, subject to approvals). These wins validate cross-sell and platform integration value.

- Exchange dynamics: continuing decline in exchange membership in certain markets; company models a cautious ~40% decline in exchange membership for specialty T&S in 2026 (they note early indicators may be slightly better, and expect clarity by end of Q2). Exchange-related servicing costs weighed on Q1 results but are expected to normalize after disenrollments in late Q2.

- Oncology remains the focal growth area: management believes Evolent manages ~10% of the oncology market today and expects outsourcing and complexity to drive meaningful market share gains over time. Oncology prevalence elevated Q1 in a few markets, impacting MER; contractual protections expected to address some of that later in the year.

- AI & automation: management targeting ~80% automation of authorization volume over time; initial AI models in imaging increased auto approvals in the high teens and in some cases up to 30% with minimal clinical value loss. New Chief Product Officer (Archie Mayani) added to accelerate product and automation roadmap.

- Capital structure and cash flow: unrestricted cash $142M, net debt $792M, no debt maturities until 2029. Company expects FY 2026 operating cash flow of $10M–$20M after ~$60M cash interest, and $25M–$30M in capex/software development.

- Quarterly cadence: Q2 adjusted EBITDA expected in line with Q1; projected sequential improvements of $10M–$15M in each of Q3 and Q4 as new launches ramp and reserves normalize (MER expected to peak in Q3 due to launch-related reserves and seasonality then improve through year-end).

- Risks/near-term noise: reserve building for new Performance Suite launches (temporarily increases MER), exchange disenrollment timing and grace-period servicing costs, localized oncology prevalence spikes. Management emphasizes contractual protections and that some Q1 pressures are temporary or subject to later true-ups.